OK-432 as a sclerosing agent to treat wound-healing impairment.
We report on the application of OK-432 (picibanil) in a patient with prolonged wound healing impairment. A 13-year-old girl had suffered a polytrauma with a displaced fracture of the sacrum which required neurosurgical decompression of the sacral plexus. Postoperatively, a seroma with recurrent fistulation was seen. Excision of the wound, prolonged suction drainage and the instillation of hypertonic glucose solution did not have any effect over a period of four months postoperatively. Relying on our personal experience of the treatment of lymphangiomas using OK-432 we instilled OK-432 into the wound. Leakage stopped immediately, there was a regression of fluid accumulation and four weeks later the ultrasound examination was normal. The patient is still asymptomatic four years after treatment. OK-432 can be used effectively for the treatment of chronic wound healing impairment.
Fasching
G
G
Department of Paediatric Surgery, General Hospital Klagenfurt, St. Veiter Strasse 47, Klagenfurt, Austria. g.fasching@lkh-klu.at
Sinzig
M
M
D000287:Administration, Topical; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008160:Lumbosacral Plexus / Q000293:injuries*; D009104:Multiple Trauma / Q000601:surgery*; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D012447:Sacrum / Q000293:injuries*; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000601:surgery*; D013529:Surgical Wound Dehiscence / Q000473:pathology / Q000628:therapy*; D014945:Wound Healing / Q000187:drug effects*
D000970:Antineoplastic Agents; D012597:Sclerosing Solutions; D010844:Picibanil